Investigator-Initiated Trials (IITs) represent a cornerstone of modern clinical research, enabling independent investigators to explore novel therapeutic applications, biomarker-driven strategies, and patient-specific treatment paradigms that extend beyond the scope of industry-sponsored programs. Protheragen, as a dedicated Radiopharmaceutical CRDMO and CRO partner, offers comprehensive IIT Clinical Services designed to empower investigators and research institutions with the regulatory expertise, operational infrastructure, and scientific rigor required to execute high-quality, compliant clinical trials—from preclinical validation through IIT execution.
Investigator-Initiated Trials (IITs) are clinical studies conceived, designed, and led by qualified investigators or academic institutions rather than commercial sponsors. In the context of radiopharmaceutical development, IITs serve as a critical mechanism for generating early human data on novel radiolabeled compounds, exploring off-label applications of approved agents, and validating biomarker-driven patient selection strategies. These trials are particularly valuable in oncology, where radiopharmaceutical therapies—such as peptide receptor radionuclide therapy (PRRT), targeted alpha therapy, and theranostic pairs—require rigorous clinical evaluation to establish safety profiles, optimal dosing regimens, and therapeutic efficacy.
Fig 1. Investigator Initiated Trial workflow within BISR. (Mudaranthakam, Dinesh Pal, et al., 2020)
The radiopharmaceutical landscape is undergoing rapid transformation, driven by advances in theranostics, alpha-emitting radionuclides, and precision dosing methodologies. However, the execution of IITs in this domain presents distinct challenges that differ significantly from traditional pharmaceutical trials. The table below outlines the primary operational, regulatory, and technical hurdles alongside corresponding strategic solutions that underpin successful trial delivery.
| Challenge Category | Key Issues | Strategic Solutions |
|---|---|---|
| Regulatory & Ethics Complexity | Multi-agency submissions (IND, IRB/EC, radiation safety boards); evolving global guidelines for novel radionuclides; compliance with ICH-GCP and local radiation regulations. | Dedicated regulatory affairs teams with radiopharmaceutical expertise; centralized IRB/EC coordination; proactive engagement with health authorities throughout the trial lifecycle. |
| Radiation Safety & Dosimetry | Balancing therapeutic efficacy against healthy tissue exposure; lack of standardized dosimetry protocols; need for organ- and tumor-specific dose estimation. | Integration of quantitative SPECT/CT and PET/CT imaging; validated dosimetry software (e.g., OLINDA, MIRD schema); patient-specific dose optimization based on time-activity curves. |
| Site Infrastructure & Qualification | Requirement for shielded facilities, radiopharmacy labs, and certified personnel; scanner calibration and phantom-based qualification; extended startup timelines. | Pre-qualified site networks with master agreements; centralized site training on imaging protocols and radiation safety; real-time technical support and credentialing programs. |
| Supply Chain & Logistics | Short half-lives of isotopes (e.g., Ga-68, Tc-99m) requiring just-in-time delivery; cold-chain integrity; coordination between CDMOs, sites, and patient scheduling. | Integrated clinical-supply teams with 24/7 tracking; slot allocation systems aligning IP availability with patient visits; contingency protocols for shipment delays or cancellations. |
| Imaging Integration & Data Quality | Harmonization of PET/SPECT acquisition protocols across multi-center trials; quantitative image reconstruction; management of large imaging datasets with biomarker correlation. | Standardized imaging manuals and phantom-based calibration; centralized image analysis core labs; validated electronic data capture (EDC) systems with imaging data integration. |
| Patient Recruitment & Retention | Narrow eligibility criteria for rare or advanced malignancies; fragile patient populations; need for multidisciplinary tumor board coordination. | Community-engaged recruitment strategies; flexible screening windows; close collaboration between nuclear medicine and oncology departments; patient-centric trial design. |
Protheragen delivers a full spectrum of IIT Clinical Services tailored specifically for the radiopharmaceutical sector, bridging the gap between scientific innovation and clinical execution. From protocol conception and regulatory navigation to on-site operational management, imaging data integration, and final statistical reporting, our integrated CRDMO and CRO platform provides investigators with the infrastructure, expertise, and compliance frameworks necessary to transform research hypotheses into high-impact clinical evidence. Whether you are exploring novel theranostic agents, validating alpha-emitter therapies, or investigating biomarker-driven patient stratification, Protheragen stands as your strategic partner in advancing radiopharmaceutical science through rigorous, ethically sound, and operationally efficient IIT execution.
We work with investigators to design rigorous, ethical and executable radiopharmaceutical IIT protocols, covering therapeutic rationale, endpoint definition, statistical design and biomarker strategies. We prepare full ethics submission documents including protocols, consent forms and risk assessments to meet IRB/EC and radiation safety requirements.
We provide full-process regulatory support for radiopharmaceutical IITs, including IND/CTA submission, multi-site ethics coordination and authority communication. We maintain GCP-compliant documentation and risk control, complying with FDA, EMA, NMPA and local radiation regulatory standards throughout trials.
We conduct site feasibility evaluation to screen qualified centers with professional imaging, radiopharmacy and certified teams. We manage contracts, budgets, site training, patient enrollment and real-time quality supervision to ensure trial progress and milestone delivery.
We adopt validated EDC systems and integrated imaging repositories to collect and manage clinical, laboratory and imaging data. We support imaging protocol formulation, device calibration, centralized image review and quantitative dosimetry analysis, fully compliant with GCP and ALCOA+ data integrity standards.
We deliver one-stop clinical supply management including GMP production, quality release, cold-chain transportation and on-site dose preparation. With real-time tracking and flexible scheduling, we optimize inventory forecasting, reduce radioactive waste and comply with radioactive transport regulations.
We provide full-cycle biostatistical support including sample size calculation, interim analysis and adaptive design. We integrate imaging quantitative metrics with clinical outcomes, delivering statistical plans, clinical study reports, manuscripts and regulatory submission materials.
Protheragen's IIT Clinical Services follow a structured, phase-gated workflow designed to ensure regulatory compliance, operational efficiency, and scientific integrity at every stage of the trial lifecycle. From initial concept to final report delivery, our integrated teams coordinate seamlessly to mitigate risks, accelerate timelines, and generate high-quality clinical evidence.
Whether you are planning your first radiopharmaceutical IIT or seeking a strategic partner to advance an ongoing investigator-led program, Protheragen is ready to support your vision with the expertise, infrastructure, and commitment to excellence that your research deserves. Reach out to us today to discuss how our IIT Clinical Services can accelerate your path from scientific hypothesis to clinical impact. Contact our clinical strategy team to schedule a consultation and explore a tailored partnership approach.
Reference